论文部分内容阅读
目的探究吲达帕胺联合缬沙坦对高血压并糖尿病患者临床疗效及血压的影响。方法选取2015年7月-2016年7月收治的150例高血压并糖尿病患者临床资料进行分析,按照治疗方式的不同,将其分成对照组(75例)与研究组(75例),对照组予以缬沙坦进行治疗,研究组于对照组基础上加用吲达帕胺进行联合治疗,观察两组肾功能指标、血压变化情况以及生化指标水平。结果研究组各项指标均低于对照组(P<0.05);研究组治疗后DBP、SBP水平均较对照组低(P<0.05);两组治疗前生化指标各项水平均较治疗后高(P<0.05),研究组治疗后各项生化指标水平与对照组比改善状态更优(t=2.301、23.687、3.935,均P<0.05)。结论吲达帕与缬沙坦联合治疗可有效改善糖尿病并高血压患者肾功能状态以及血压水平,有效提高临床疗效与预后情况。
Objective To investigate the effect of indapamide combined with valsartan on the clinical efficacy and blood pressure in hypertensive diabetic patients. Methods The clinical data of 150 patients with hypertension and diabetes mellitus admitted from July 2015 to July 2016 were analyzed. According to the different treatment methods, they were divided into control group (75 cases) and study group (75 cases), control group The patients were treated with valsartan. The study group was treated with indapamide on the basis of the control group, and the renal function, blood pressure and biochemical indexes were observed. Results All the indexes in the study group were lower than those in the control group (P <0.05). The levels of DBP and SBP in the study group were lower than those in the control group (P <0.05) (P <0.05). All the biochemical indexes in the study group were better than those in the control group (t = 2.301,23.687,3.935, all P <0.05). Conclusion The combination of indapamide and valsartan can effectively improve renal function and blood pressure in patients with diabetes mellitus and hypertension, and effectively improve the clinical efficacy and prognosis.